<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947761</url>
  </required_header>
  <id_info>
    <org_study_id>TWBXDPOD</org_study_id>
    <nct_id>NCT04947761</nct_id>
  </id_info>
  <brief_title>Modified Tian Wang Bu Xin Dan Hydrogel Patch in Preventing Postoperative Delirium in Elderly Patients</brief_title>
  <official_title>Modified Tian Wang Bu Xin Dan Hydrogel Patch in Preventing Postoperative Delirium in Elderly Patients: A Muticenter Randomised Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preoperative administration of Modified&#xD;
      Tian Wang Bu Xin Dan Hydrogel Patch prevents the incidence of postoperative delirium in&#xD;
      elderly patients undergoing major surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Traditional Chinese Medicine (TCM) Tian Wang Bu Xin Dan (TWBXD, Cheonwangbosimdan), first&#xD;
      recorded in Effective Formulae Handed Down for Generations ( Shi Yi De Xiao Fang) in 1337, is&#xD;
      a herbal medicine that has been continuously utilized in Chinese medicine. It alleviates&#xD;
      insomnia, anxiety, and palpitation by furnishing energy and stabilizing patients' mind.&#xD;
      Cheonwangbosimdan can mitigate primary insomnia and secondary insomnia in patients with&#xD;
      hyperthyroidism and menopause without severe side effects.&#xD;
&#xD;
      Tianwang Buxin Decoction has the same effect as Olanzapine for the treatment of delirium&#xD;
      after hip joint replacement in falling-induced senile femoral neck fracture patients.&#xD;
&#xD;
      This study aim to evaluate the incidence of postoperative delirium in elderly patients&#xD;
      treated with prophylactic Modified Cheonwangbosimdan Hydrogel Patch versus placebo patch.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of inpatient post-operative delirium as measured using the 3D-confusion assessment method (3D-CAM)</measure>
    <time_frame>Day 1 postoperatively</time_frame>
    <description>Occurrence of delirium on any postoperative day, as assessed using the 3D-CAM or CAM-ICU daily</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of inpatient post-operative delirium as measured using the 3D-confusion assessment method (3D-CAM)</measure>
    <time_frame>Day 2 postoperatively</time_frame>
    <description>Occurrence of delirium on any postoperative day, as assessed using the 3D-CAM or CAM-ICU daily</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of inpatient post-operative delirium as measured using the 3D-confusion assessment method (3D-CAM)</measure>
    <time_frame>Day 3 postoperatively</time_frame>
    <description>Occurrence of delirium on any postoperative day, as assessed using the 3D-CAM or CAM-ICU daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>Baseline and 1,3 days after surgery</time_frame>
    <description>Objective sleep quality will be measured using a Fitbit Charge 3 activity monitor to be worn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Athens Insomnia Scale</measure>
    <time_frame>Baseline and 1,2,3 days after surgery</time_frame>
    <description>using the Athens Insomnia Scale to test the subjective sleep quality of patients. The range were from 0-3. Total score &lt; 4 means sleep well; total score =6 means suspicious of insomnia; total score &gt; 6 means insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest using Numerical Rating Scale(NRS)</measure>
    <time_frame>postoperative days 1, 2, 3</time_frame>
    <description>NRS pain scores will also be measured at rest. The NRS is a validated 11-point numerical scale that ranges from 0 (no pain) to 10 (worst pain possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total postoperative analgesic requirements</measure>
    <time_frame>First 48 hours postoperatively</time_frame>
    <description>Amount of opioid (IV morphine or hydromorphone) and oral analgesics required for pain control, reported as overall morphine equivalents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biological markers (1)</measure>
    <time_frame>Baseline and 1 day after surgery</time_frame>
    <description>Plasma levels of CXCL13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biological markers (2)</measure>
    <time_frame>Baseline and 1 day after surgery</time_frame>
    <description>Plasma levels of S100B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STOP-Bang score</measure>
    <time_frame>Baseline</time_frame>
    <description>STOP-BANG questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>Baseline and day 3 postoperatively</time_frame>
    <description>The PSQI is filled out by the patient and assesses patient sleep quality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>modified Cheonwangbosimdan Hydrogel patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving modified Cheonwangbosimdan Hydrogel patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modified Tian Wang Bu Xin Dan hydrogel patch</intervention_name>
    <description>modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)</description>
    <arm_group_label>modified Cheonwangbosimdan Hydrogel patch</arm_group_label>
    <other_name>modified Cheonwangbosimdan hydrogel patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo patch</intervention_name>
    <description>placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)</description>
    <arm_group_label>Placebo patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients' age â‰¥70 years;&#xD;
&#xD;
          2. Underwent elective non-cardiac surgery (including Orthopedics, thoracic, urology,&#xD;
             general surgery patients)under general anesthesia ;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of neuropsychiatric diseases including delirium, mental disorders, Parkinson,&#xD;
             dementia, etc.;&#xD;
&#xD;
          2. The operation was cancelled due to various reasons after the patient was enrolled;&#xD;
&#xD;
          3. severe liver disease; severe renal dysfunction defined as either having creatinine&#xD;
             clearance &lt; 30 ml/min or being dialysis-dependent;&#xD;
&#xD;
          4. Patients who undergo second operation in a short period;&#xD;
&#xD;
          5. Past 30-day prescribed use of sedative-hypnotics for the indication of insomnia;&#xD;
&#xD;
          6. History of alcohol abuse or a history of drug dependence;&#xD;
&#xD;
          7. Cannot with the completion of tests of cognitive function;&#xD;
&#xD;
          8. Known allergy to skin patch;&#xD;
&#xD;
          9. Treatment site has active skin lesion or inflammation;&#xD;
&#xD;
         10. Refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weidong Mi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weidong Mi, PhD</last_name>
    <phone>8613381082966</phone>
    <email>wwdd1962@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunlei Ouyang, PhD</last_name>
    <phone>+8618810300815</phone>
    <email>ouyangchunlei@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fifth Medical center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingqun Yu, PhD</last_name>
      <phone>8613521558519</phone>
      <email>yuyingqun@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Medical center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Mi, PhD</last_name>
      <phone>+8613381082966</phone>
      <email>wwdd1962@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth Medical center of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengmeng Li, PhD</last_name>
      <phone>8613401000778</phone>
      <email>mmli304@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Weidong Mi</investigator_full_name>
    <investigator_title>Director (Cheif expert of National key research and development program of China 2018YFC2001900)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

